NZ529513A - Toluene sulfonamide-containing anti-tumor composition and method of use thereof - Google Patents

Toluene sulfonamide-containing anti-tumor composition and method of use thereof

Info

Publication number
NZ529513A
NZ529513A NZ529513A NZ52951302A NZ529513A NZ 529513 A NZ529513 A NZ 529513A NZ 529513 A NZ529513 A NZ 529513A NZ 52951302 A NZ52951302 A NZ 52951302A NZ 529513 A NZ529513 A NZ 529513A
Authority
NZ
New Zealand
Prior art keywords
toluene sulfonamide
pharmaceutical composition
composition
para
toluene
Prior art date
Application number
NZ529513A
Other languages
English (en)
Inventor
John Wu
Rocky C S Shih
Lester Wu
Original Assignee
Pts International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pts International Inc filed Critical Pts International Inc
Publication of NZ529513A publication Critical patent/NZ529513A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ529513A 2001-04-16 2002-04-16 Toluene sulfonamide-containing anti-tumor composition and method of use thereof NZ529513A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/835,908 US6727287B2 (en) 2001-04-16 2001-04-16 Toluene sulfonamide-containing anti-tumor composition and method of use thereof
PCT/US2002/011786 WO2002083117A1 (en) 2001-04-16 2002-04-16 Toluene sulfonamide-containing anti-tumor composition and method of use thereof

Publications (1)

Publication Number Publication Date
NZ529513A true NZ529513A (en) 2005-10-28

Family

ID=25270767

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ529513A NZ529513A (en) 2001-04-16 2002-04-16 Toluene sulfonamide-containing anti-tumor composition and method of use thereof

Country Status (16)

Country Link
US (1) US6727287B2 (enExample)
EP (1) EP1389101B1 (enExample)
JP (1) JP2004526760A (enExample)
CN (1) CN100471491C (enExample)
AT (1) ATE415960T1 (enExample)
AU (1) AU2002303350B2 (enExample)
BR (1) BR0208961A (enExample)
CA (1) CA2444842A1 (enExample)
DE (1) DE60230133D1 (enExample)
EA (1) EA007685B1 (enExample)
ES (1) ES2316565T3 (enExample)
IL (2) IL158433A0 (enExample)
MX (1) MXPA03009483A (enExample)
NZ (1) NZ529513A (enExample)
WO (1) WO2002083117A1 (enExample)
ZA (1) ZA200308814B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005397B4 (de) * 2005-02-05 2008-08-21 Lts Lohmann Therapie-Systeme Ag Isolierung von N-Butylbenzolsulfonamid, Synthese von Benzolsulfonamid-Derivaten sowie Verwendung von N-Butylbenzolsulfonamid und Benzolsulfonamid-Derivaten zur Behandlung der benignen Prostatahyperplasie und/oder des Prostatakarzinoms
US7790928B1 (en) * 2005-04-25 2010-09-07 Albert Raymond Hechinger Therapeutic dimethyl sulfoxide (aka DMSO) compositions and methods of use
EP1976495A2 (en) * 2006-01-06 2008-10-08 Aarhus Universitet Compounds acting on the serotonin transporter
CN104473914B (zh) * 2015-01-06 2017-01-11 天津红日药业股份有限公司 一种磺酰胺类药物组合物
US10465742B2 (en) 2015-10-29 2019-11-05 Inteva Products, Llc Cable end fitting and cable abutment and method of securement
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
US10182998B2 (en) * 2016-06-10 2019-01-22 Gongwin Biopharm Holdings Co., Ltd. Benzenesulfonamide compositions for treatment of malignant pleural effusions
US9668990B1 (en) * 2016-06-10 2017-06-06 Gongwin Biopharm Holdings Co., Ltd. Benzenesulfonamides compositions for treatment of malignant pleural effusions
US20180055796A1 (en) 2016-08-23 2018-03-01 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical composition exhibiting anti-tumor activity, method for treating patient suffering from cancer and method for inhibiting tumor growth
KR20250020713A (ko) * 2017-12-29 2025-02-11 공윈 바이오팜 컴퍼니, 리미티드 벤젠술폰아미드 유도체 및 지질 래프트 조정 방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340148A (en) 1961-03-22 1967-09-05 Gillette Inhibitor Co Treatment of fungus diseases of the skin
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4777049A (en) 1983-12-01 1988-10-11 Alza Corporation Constant release system with pulsed release
US4663308A (en) 1984-07-18 1987-05-05 Medical College Of Ohio Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract
US4764381A (en) 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
US4983396A (en) 1985-12-06 1991-01-08 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1,3-hexanediol
US5891454A (en) 1997-03-28 1999-04-06 Alexander Wu Anti-cancer drug and special tumor necrotizing agent
CN1073415C (zh) 1997-07-03 2001-10-24 吴宜庄 磺酰胺类化合物在制备抗癌药物中的应用

Also Published As

Publication number Publication date
IL158433A0 (en) 2004-05-12
ATE415960T1 (de) 2008-12-15
MXPA03009483A (es) 2004-12-06
HK1067545A1 (zh) 2005-04-15
EP1389101B1 (en) 2008-12-03
US20030022843A1 (en) 2003-01-30
ZA200308814B (en) 2004-11-23
WO2002083117A1 (en) 2002-10-24
CN1511032A (zh) 2004-07-07
EA007685B1 (ru) 2006-12-29
EP1389101A1 (en) 2004-02-18
ES2316565T3 (es) 2009-04-16
JP2004526760A (ja) 2004-09-02
DE60230133D1 (de) 2009-01-15
CN100471491C (zh) 2009-03-25
EA200301126A1 (ru) 2004-06-24
AU2002303350B2 (en) 2007-08-02
EP1389101A4 (en) 2005-05-04
BR0208961A (pt) 2005-02-01
US6727287B2 (en) 2004-04-27
CA2444842A1 (en) 2002-10-24
IL158433A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
US9907787B2 (en) Method of supplementing the diet and ameliorating oxidative stress
US8426368B2 (en) Method of ameliorating oxidative stress and supplementing the diet
AU2002303350B2 (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
AU2002303350A1 (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
JP5850518B2 (ja) 高分子化環状ニトロキシドラジカル化合物の潰瘍性消化管の炎症の処置剤
IL280371A (en) Mucoadhesive dispersion nanoparticle system and method for production the same
KR20030019612A (ko) 골전이 치료에서 에스트라무스틴 포스페이트의 용도
JP2008528640A (ja) バイカレインとバイカリンとの抗腫瘍相乗医薬組成物
HK1067545B (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof
CN109730988A (zh) 1，3-丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途
EP1075257A1 (en) Use of triclosan for the treatment of helicobacter pylori infections
KR101221640B1 (ko) 자궁 종양 치료용 약제의 제조를 위한7-티-부톡시이미노메틸캄토테신의 용도
WO2025185023A1 (zh) 新藤黄酸脂肪体及其制备方法与应用
JP2006117569A (ja) ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬
HK40068937B (zh) 癌症治疗方法
US20040254123A1 (en) Malignant cell differentiation inducer compositions and utilization of the same
WO2009071405A1 (en) Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients
HK1256017B (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
HK1256017A1 (en) Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of cancer
WO2009111555A1 (en) Combination treatment for bladder cancer comprisining valrubicin and trospium chloride

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2016 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20150303

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2017 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20160308

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2018 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20170309

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2019 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20180412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 APR 2020 BY PHILLIPS ORMONDE FITZPATRICK

Effective date: 20190122

LAPS Patent lapsed